WO2011070380A1 - New process for the preparation of dronedarone - Google Patents

New process for the preparation of dronedarone Download PDF

Info

Publication number
WO2011070380A1
WO2011070380A1 PCT/HU2010/000128 HU2010000128W WO2011070380A1 WO 2011070380 A1 WO2011070380 A1 WO 2011070380A1 HU 2010000128 W HU2010000128 W HU 2010000128W WO 2011070380 A1 WO2011070380 A1 WO 2011070380A1
Authority
WO
WIPO (PCT)
Prior art keywords
process according
general formula
reaction
carried out
compound
Prior art date
Application number
PCT/HU2010/000128
Other languages
French (fr)
Inventor
Antal Friesz
Zsolt DOMBRÁDY
Marianna CSATÁRINĖ NAGY
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2010329655A priority Critical patent/AU2010329655B2/en
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to MX2012006654A priority patent/MX2012006654A/en
Priority to CN2010800629901A priority patent/CN102741238A/en
Priority to CA2781647A priority patent/CA2781647A1/en
Priority to BR112012013753A priority patent/BR112012013753A2/en
Priority to RU2012128568/04A priority patent/RU2012128568A/en
Priority to JP2012542624A priority patent/JP2013512944A/en
Priority to SG2012041927A priority patent/SG181562A1/en
Priority to EP10809325A priority patent/EP2509971A1/en
Publication of WO2011070380A1 publication Critical patent/WO2011070380A1/en
Priority to US13/479,615 priority patent/US8501971B2/en
Priority to IL220170A priority patent/IL220170A0/en
Priority to US13/905,624 priority patent/US8889734B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Definitions

  • the present invention relates to novel process for the preparation of the N- [2- «-butyl-3- ⁇ 4-[(3-dibutylamin0)-propoxy]benzoyl ⁇ -l-benzofuran-5-yl]methane- sulfonamide (dronedarone) of formula I and its pharmaceutically acceptable salts, and to the new intermediates of the reparation process.
  • Dronedarone of formula I is used in the treatment of certain pathological changes of the cardiovascular system, especially in the treatment of angina pectoris, high blood pressure, arrhythmia and insufficient cerebral blood circulation (EP 0471609 B l).
  • One reactant is dibutylamine, which is volatile and thus can be removed from the system and reused after workup, the other is a compound of the general formula (II) -where the meaning of X is as defined above- which can be treated well under the applied reaction conditions.
  • dronedarone of formula (I) is obtained in appropriate purity and yield, no byproduct is formed, only a few percent of the unreacted starting material may remain in the reaction mixture, and this can be reused.
  • the reaction of the compound of the general formula (II) -wherein X stands for chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group- with dibutylamine is carried out using equivalent amount or excess of dibutylamine.
  • the reaction is performed in an organic solvent or in a mixture of organic solvents.
  • organic solvent ketones (acetone, methyl ethyl ketone), for mixture of organic solvents, mixtures of ketones and aromatic hydrocarbons (xylene, toluene) are used.
  • other organic solvents and their mixtures can also be used. .
  • the compound of the general formula (II) -where the meaning of X is as defined above- is reacted with dibutylamine, optionally in the presence of a catalyst. If in the general formula (II) the meaning of X is chloro- or bromo atom, then iodides (as for example sodium iodide or potassium iodide) are used as catalyst.
  • the hydroxyl group may be activated with methylsulfonyl or substituted benzenesulfonyl group.
  • the substituent of the benzenesulfonyl group may be C 1 . 4 -alkyl group, halogen atom or nitro group.
  • Y stands for chloro- or bromo atom
  • X represents halogen atom or protected hydroxy 1 group
  • the thus obtained compound of formula (II) -where the meanings of X are defined above- is reacted with dibutylamine in a manner as described above, to obtain dronedarone of formula (I).
  • reaction of the benzofuran derivative of formula (III) with the acid halide of the general formula (IV) - where the meanings of X and Y are as defined above- is carried out in the presence of Friedel-Crafts catalyst in a halogenated organic solvent or in nitrobenzene.
  • reaction of the compounds (III) and (IV) is carried out in a temperature range of 10-80 °C.
  • the hydrogenation reaction of the compound of formula (VI) is carried out in the presence of a catalyst.
  • a catalyst In one version of the method palladium catalyst is used. In another version of the method platinum catalyst is applied.
  • the hydrogenation reaction of the compound of formula (VI) is performed in an organic solvent, in a temperature range of 10-80 °C.
  • the mesylation of the compound of formula (V) is carried out with methanesulfonyl chloride or with methanesulfonic anhydride.
  • the mesylation of the compound of formula (V) is performed in an inert solvent.
  • ether or a halogenated solvent is used.
  • the mesylation of the compound of formula (V) is carried out in a temperature range of 5-80 °C.
  • the mesylation of the compound of formula (V) is carried out in the presence of a base.
  • an amine pyridine, triethylamine
  • X stands for chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group; .
  • X stands for chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group are new compounds, not known from the literature.
  • the compounds of the general formula (II), where the meanings of X are defined above are prepared by reacting the compounds of formula (III) with the compounds of the general formula (IV) - wherein Y stands for chloro- or bromp atom, and X represents a halogen atom or a protected hydroxyl group.
  • the compound of formula (III) is known, its preparation by mesylation of 5-amino-2- «-butyl-benzofuran is described in patent application WO 02/048132.
  • the compounds of the general formula (IV) wherein the meanings of X and Y are defined above, are also known from the literature, their preparation is disclosed in patent EP 0471609 Bl.
  • the compounds of the general formula (II) - where the meaning of X is defined above - are prepared by mesylation of a compound of the general formula (V) - wherein X means chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group.
  • the compound of the general formula (V) - where the meaning of X is defined above - is prepared by catalytic hydrogenation of the benzofuran derivative of the general formula (VI) - where the meaning of X is defined above.
  • the compound of the general formula (VI), wherein X represents bromo atom is known from the literature.
  • Example 2 The process as described in Example 2. was followed, starting from (2- «-but l-5-nitro-l-benzofuran-3-yl)-[4-(3-bromopropoxy)phenyl]methanone -the compound of the general formula (VI) where X is bromo atom.
  • the product is identical with the product prepared in Example 4.
  • Example 10 The product is identical with the product prepared in Example 5. Example 10.
  • the product is purified through its oxalate salt (90%).
  • the product is identical with the product prepared in Example 12. -
  • the product is identical with the product prepared according to Example 12.
  • Example 20 Example 20.
  • dronedarone base 5 g was dissolved in 24 ml isopropanol and 0.98 g 37% hydrochloric acid was added to it. The mixture was cooled to 0°C and kept at that temperature for 5 hours. The precipitated white crystals were collected, washed with 3.5 ml isopropanol. The product was dried at 50°C under vacuum.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The subject of the present invention is a novel process for the preparation of N- [2-n-butyl-3-{4-[(3-dibutylamino)propoxy]benzoyl}-1-benzofuran-5- yl] methanesulfonamide of formula (I) and the new intermediates of the preparation process.

Description

New process for the preparation of dronedarone
The present invention relates to novel process for the preparation of the N- [2-«-butyl-3-{4-[(3-dibutylamin0)-propoxy]benzoyl}-l-benzofuran-5-yl]methane- sulfonamide (dronedarone) of formula I and its pharmaceutically acceptable salts, and to the new intermediates of the reparation process.
Figure imgf000002_0001
Dronedarone of formula I is used in the treatment of certain pathological changes of the cardiovascular system, especially in the treatment of angina pectoris, high blood pressure, arrhythmia and insufficient cerebral blood circulation (EP 0471609 B l).
There are several known methods for the preparation of dronedarone of formula I. One prior art process (EP 0471609 B l) reacts 2-hydroxy-5-nitro- benzylbromide (VII)
Figure imgf000002_0002
with triphenylphosphine, and the thus obtained 2-hydroxy-5-nitro-benzyl-triphenyl- phosphonium bromide (VIII)
Figure imgf000003_0001
is reacted with pentanoyl chloride to give 2-«-butyl-5-nitro-benzoruran (IX)
Figure imgf000003_0002
IX
Treatment of IX with anisoyl chloride under Friedel-Crafts conditions gives 2-n- butyl-3-(4-methoxy-benzoyl)-5-nitro-benzofuran (X)
Figure imgf000003_0003
which is heated in the presence of aluminum chloride to obtain 2-n-butyl-3-(4- hydroxy-benzoyl)-5-nit -benzofuran (XI)
Figure imgf000003_0004
XI Industrial application of this last reaction step involves difficulties, because 2-n- butyl-3-(4-methoxybenzoyl)-5-nitro-benzofuran (X) is mutagenic, and aluminum chloride is harmful for the health. The resulting 2-«-butyl-3-(4-hydroxybenzoyl)-5- nitro-benzofuran (XI) on reaction with dibutylamino-propylchloride furnishes 2-n- butyl-3-[4 (3 I)
Figure imgf000004_0001
XII which is reduced in the presence of platinum oxide catalyst to the 5-amino-2-«-
Figure imgf000004_0002
Figure imgf000005_0001
XIV and the thus obtained 2-«-butyl-3-[4-(3-dibutylamino-propoxy)benzoyl]-5-nitro- benzofuran (XII) is reduced in the presence of platinum oxide catalyst to the 5- amino-2-«-butyl-3-[4-(3-dibutylamino-propoxy)benzoyl]benzofuran (XIII).
Mesylation of the latter gives dronedarone (I). In the course of the last, mesylation step, however, a double mesylated derivative is also formed, the yield is low and the purification of dronedarone by column chromatography is complicated. The industrial application of the method is therefore not economical.
The third known method for the preparation of dronedarone (I) is disclosed in patent application of publication number WO 02/48132. This superrconvergent method contains the following steps:
5-amino-2-n-butyl-benzofuran (XV)
Figure imgf000005_0002
XV is mesylated and the resulting 2-«-butyl-5-mesylamino-benzofuran (III)
Me
nBu is reacted with 4-[3-(dibutylamino)propoxy]benzoyl chloride hydrochloride salt (XlVa)
Figure imgf000006_0001
XlVa under Friedel-Crafts conditions, to obtain the hydrochloride salt of dronedarone (la).
Figure imgf000006_0002
la
In this method the order of the reaction steps is changed, the reduction step and the mesylation are at the beginning of the synthesis.
This method is very simple and economical regarding the number of the reaction steps. Its drawback is, however, that in the last step the hydrochloride salt of dronedarone is obtained in a substantially contaminated form. This can be explained by the presence of the dibutylamino-propyl group in the Friedel-Crafts reaction. In the published examples the yield is 90%, during the purification steps first the raw dronedarone hydrochloride, then, following treatment with hydrogen chloride solution in isopropanol, the purified dronedarone hydrochloride is obtained (90%). . .
Another drawback of the method is that the reactants used in the Friedel- Crafts reaction and the obtained by-products are insoluble in water, thus they cannot be removed from the system by aqueous washing. Our aim was to work out a novel method for the preparation of dronedarone and its pharmaceutically acceptable salts, which method avoids the above mentioned disadvantages, and is economical and industrially applicable.
We have
-wherein
Figure imgf000007_0001
activated hydroxyl group- is reacted with dibutylamine, and optionally transformed into its salts, then this method avoids the disadvantages of the processes mentioned before, it is economical and also suitable for industrial application.
One reactant is dibutylamine, which is volatile and thus can be removed from the system and reused after workup, the other is a compound of the general formula (II) -where the meaning of X is as defined above- which can be treated well under the applied reaction conditions. By choosing suitable reaction conditions, dronedarone of formula (I) is obtained in appropriate purity and yield, no byproduct is formed, only a few percent of the unreacted starting material may remain in the reaction mixture, and this can be reused.
According to our invention the reaction of the compound of the general formula (II) -wherein X stands for chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group- with dibutylamine is carried out using equivalent amount or excess of dibutylamine. The reaction is performed in an organic solvent or in a mixture of organic solvents. For organic solvent, ketones (acetone, methyl ethyl ketone), for mixture of organic solvents, mixtures of ketones and aromatic hydrocarbons (xylene, toluene) are used. Optionally other organic solvents and their mixtures can also be used. .
According to our invention the compound of the general formula (II) -where the meaning of X is as defined above- is reacted with dibutylamine, optionally in the presence of a catalyst. If in the general formula (II) the meaning of X is chloro- or bromo atom, then iodides (as for example sodium iodide or potassium iodide) are used as catalyst. If in the general formula (II) the meaning of X is hydroxyl group, then [Ru( -cymene)Cl2]2 and 1,1 '-bis-(diphenylphosphino) ferrocene or [Ru( - cymene)Cl2]2 and bis-(2-diphenylphosphinophenyl)ester compounds are used. If in the general formula (II) the meaning of X is iodo atom or activated hydroxyl group, then no catalyst is used.
. The reaction of the compound of the general formula (II) -wherein X stands for chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group- with dibutylamine is carried out at the boiling point of the applied solvents or between 60-120°C.
In the compounds of the general formula (II) the hydroxyl group may be activated with methylsulfonyl or substituted benzenesulfonyl group. The substituent of the benzenesulfonyl group may be C1.4-alkyl group, halogen atom or nitro group.
According to one embodiment of our invention the 2-«-butyl-5-mesylamino- benzofuran (III)
Figure imgf000008_0001
is reacted with an acid halide of the general formula (IV)
Figure imgf000009_0001
IV
where
Y stands for chloro- or bromo atom, X represents halogen atom or protected hydroxy 1 group, and the thus obtained compound of formula (II) -where the meanings of X are defined above- is reacted with dibutylamine in a manner as described above, to obtain dronedarone of formula (I).
According to our invention the reaction of the benzofuran derivative of formula (III) with the acid halide of the general formula (IV) - where the meanings of X and Y are as defined above- is carried out in the presence of Friedel-Crafts catalyst in a halogenated organic solvent or in nitrobenzene.
The reaction of the compounds (III) and (IV) is carried out in a temperature range of 10-80 °C.
According to another embodiment of the invention, a compound of the general formula t (VI),
Figure imgf000009_0002
VI
wherein X represents chloro-, bromo- or iodo atom, hydroxy^ or activated hydroxyl group, is subjected to hydrogenation reaction and the thus obtained compound of the general formula (V)
Figure imgf000010_0001
wherein X represents chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group, is mesylated and the resulting compound of formula (II) is reacted, in the above described manner with dibutylamine, to give dronedarone of formula (I). , .··
The hydrogenation reaction of the compound of formula (VI) is carried out in the presence of a catalyst. In one version of the method palladium catalyst is used. In another version of the method platinum catalyst is applied. The hydrogenation reaction of the compound of formula (VI) is performed in an organic solvent, in a temperature range of 10-80 °C.
The mesylation of the compound of formula (V) is carried out with methanesulfonyl chloride or with methanesulfonic anhydride. The mesylation of the compound of formula (V) is performed in an inert solvent. According to one preferred embodiment of the reaction, ether or a halogenated solvent is used. The mesylation of the compound of formula (V) is carried out in a temperature range of 5-80 °C. The mesylation of the compound of formula (V) is carried out in the presence of a base. According to one preferred embodiment of the reaction an amine (pyridine, triethylamine) is used as base. ·
The benzofuran derivatives of the general formula (II) (CH2 ) -X
Figure imgf000010_0002
where X stands for chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group;
the benzofuran derivatives of the eneral formula (V),
Figure imgf000011_0001
wherein X stands for chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group; .
and
the benzofuran derivatives of the general formula (VI),
Figure imgf000011_0002
wherein X stands for chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group are new compounds, not known from the literature.
In one embodiment of the present invention the compounds of the general formula (II), where the meanings of X are defined above, are prepared by reacting the compounds of formula (III) with the compounds of the general formula (IV) - wherein Y stands for chloro- or bromp atom, and X represents a halogen atom or a protected hydroxyl group. The compound of formula (III) is known, its preparation by mesylation of 5-amino-2-«-butyl-benzofuran is described in patent application WO 02/048132. The compounds of the general formula (IV) wherein the meanings of X and Y are defined above, are also known from the literature, their preparation is disclosed in patent EP 0471609 Bl.
<· In another embodiment of the present invention the compounds of the general formula (II) - where the meaning of X is defined above - are prepared by mesylation of a compound of the general formula (V) - wherein X means chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group. The compound of the general formula (V) - where the meaning of X is defined above - is prepared by catalytic hydrogenation of the benzofuran derivative of the general formula (VI) - where the meaning of X is defined above. The compound of the general formula (VI), wherein X represents bromo atom, is known from the literature. The compound itself, and its preparations are disclosed by the Applicant in patent EP 0471609 Bl. The preparation of the compounds of the general formula (VI) - wherein X means chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group - from the benzofuran derivative (XI), is carried out by analogy of the method described in EP 0471609 Bl.
Further details of the invention are demonstrated by the following examples, without limiting the claims to examples.
. '
Example 1.
(2-fl-butyl-5-nitro- 1 -benzofuran-3-yl)-r4-(3-chloropropoxy)phenyl] methanone, compound of the general formula (VI) wherein X is chloro atom
40 g (2-n-butyl-3-(4-hydroxybenzoyl)-5-nitro-benzofuran (XI) was dissolved in 320 ml methyl ethyl ketone and to the solution 48.9 g potassium carbonate was added. During stirring 37.2 g l-bromo-3-chloropropane was added and the mixture was heated to reflux (81-82°C) and stirred at that temperature for 4 hours. After cooling, the solid salt was filtered off and washed with 3 x, 20 ml methyl ethvl ketone. The filtrate was evaporated. The removed methyl ethyl ketone which r contains the excess of l-bromo-3-chloropropane is used in the next reaction.
Mass of the product: 44.93 g. (99.1%)
Purity (HPLC): 98.9%
Molecular weight: (calculated): 416.1265 Da .
(measured): 416.1274 Da
1H NMR (DMSO): 0.84ppm (t, J=7.4Hz, 3H); 1.27ppm (6\ 2H); 1.72ppm (5\ 2H); 2.26ppm (5', J=6.5Hz, 2H); 2.88ppm (t, J=6.5HZ, 2H); 3.86ppm (t,J=6.5Hz, 2H); 4.26ppm (t, J=6.0Hz; 2H); 7.17ppm (d, J=8,8Hz, 2H); 7.86ppm (d, J=8.7Hz, 2H); 7.96ppm (m, 1H); 8.29ppm (m, 1+lH) ' . -
Example 2.
(5-Amino-2-w-butyl-benzofuran-3-yl)-r4-(3-chloropropoxy)phenvn methanone, compound of the general formula (V) wherein X is chloro atom
Into a 500 ml hydrogenation reactor equipped with turbo stirrer were added 93.8 g (2-«-butyl-5-nitro-l-benzofuran-3-yl)-[4-(3-chloro-propoxy)phenyl]- methanone -the compound of the general formula (VI), where X is chloro atom- and 470 ml abs. ethanol, and then 4.9 g 10% palladium on carbon catalyst. The reaction mixture was heated to 50°C under stirring at a speed of 800 rotation/minute. Under cooling, hydrogen under 5 bar pressure was set to the reactor and the mixture was stirred at that pressure and temperature for 2 hours. After cooling the catalyst was filtered off and the solvent was removed.
Mass of product: 85.46 g (98%).
Purity (HPLC): 93.8%
Molecular weight: (calculated): 386.1523 Da
(measured): 386.1524 Da
Ή NMR (DMSO): 0.82ppm (t, J=7.4Hz, 3H); 1.24ppm (6\ 2H); 1.64ppm (5',2H); 2.22ppm (5\ 2H); 2.75ppm (t, J=7.6Hz, 2H); 3.78ppm (t, J=6.4Hz, 2H); 4.9ppm (t, J=5.9Hz, 2H); 6.62ppm (d, J=2.3Hz, IH); 6.65ppm (dd, J=8.7; 2.3Hz, - IH); 7.05ppm (d, J=8.6Hz, 2H); 7.22ppm (d, J=8.7Hz, IH); 7.77ppm (d, J=8.7Hz, 2H)
Example 3.
(5-Amino-2- -butyl-benzofuran-3-yl)- 4-(3-bromo-propoxy)phenyll methanone, compound of the general formula (V) wherein X is bromo atom
The process as described in Example 2. was followed, starting from (2-«-but l-5-nitro-l-benzofuran-3-yl)-[4-(3-bromopropoxy)phenyl]methanone -the compound of the general formula (VI) where X is bromo atom.
Yield of the product: 97.6%
Purity (HPLC): 92.4%
Molecular weight: (calculated): 430.1018 Da
(measured): 430.1032 Da
!H NMR (DMSO): 0.83ppm (t, J=6.8Hz, 3H); 1.26ppm (t, J=6.8Hz, 2H); 1.69ppm (m, 2H); 2.25ppm (m, IH); 2.33ppm (m, IH); 2.84ppm (m, 2H); 3.72ppm (m, IH); 3.86ppm (m, IH); 4.25ppm (m, 2H); 7.15ppm (d, J=8.1Hz, 2H); 7.39ppm (d, 8:1Hz, IH); 7.51ppm (S, IH); 7.82ppm (d, J=8.1Hz, 3H) '
Example 4. ,
N-(2-»-butyl-3- 4-(3-chloropropoxy)benzoyll benzofuran-5-yl) methane
sulfonamide, compound of the general formula (II) wherein X is chloro atom
8.7 g (5-amino-2-«-butyl-benzofuran-3-yl)-[4-(3-chloropropoxy)phenyl] methanone—the compound of the general formula (V) wherein X is chloro atom - was stirred in 90 ml dichloromethane until complete dissolution. The solution was cooled to 15°C and keeping this temperature 1.8 g pyridine, then dropwise, at 15°C, in 15 minutes 2.6 g methanesulfonyl chloride were added. After checking the reaction mixture by HPLC, further 0.19 g pyridine and 0.26 g methanesulfonvl chloride were added and stirring was continued for 30 minutes. The reaction mixture was washed with 2 x 20 ml water, 2 x 20 ml 5% hydrochloric acid, and 2 x
20 ml 5% NaHCO3 solution, and then it was evaporated.
Mass of the product: 10.1 g (96.6%)
Purity: 87.5%
Following crystallisation from abs. ethanol (yield 72%), the purity (by HPLC) of the product: 100%
Melting point: 109.7-1 10.3°C
Ή NMR (DMSO-D6): 9.61ppm (1H), 7.82ppm (J=8.7Hz, 2H), 7.65ppm (d, IH), 7.31 ppm (dd, J=2.1Hz, 1H), 7.24 ppm (dd, J=8.8Hz, 1H), 7.14 ppm (2H), 4.25ppm (t, J=6.0Hz, 2H), 3.85 ppm (t, J-6.4Hz, 2H), 2.92 ppm (S, 2H), 2.84ppm (t, J=7.5Hz, 2H), 2.25pprri (m, 2H), 1.69 ppm (m, 2H), 1.28ppm (m, 2H), 0.84ppm (t, J=7.3Hz, 3H) Example 5.
N-(2-ft-biity 1-3 - 4-(3 -bromopropoxy)-benzoy llbenzofuran-5 -y 1)
methanesulfonamide, compound of the general formula (II where X is bromo atom The process as described in Example 4. was followed, starting from
(5-amino-2-n-butyl-benzofuran-3-yl)-[4-(3-bromopropoxy)phenyl]methanone -the compound of the general formula (V) where X is bromo atom.
Yield of the product: 95.8% - . Purity: 86.8% (HPLC)
Molecular weight: (calculated): 508.0793 Da
(measured): 508.0780 Da
1H NMR (DMSO): 0.84ppm (t, J=7.3Hz, 3H); 1.26ppm (6', 2H); 1.69ppm (5', 2H); 2.33ppm (5', 2H); 2.84ppm (t, J=6.5Hz, 2H); 2.92ppm (s, 3H); 3.73ppm (t, J=6.5Hz, 2H); 4.23ppm (t, J=6.0Hz, 2H); 7.14ppm (d, J=8.8Hz, 2H); 7.23ppm (dd, J=8.9; 2.3Hz, 1H; 7.25ppm (d, J=2.1Hz, TH; 7.66ppm (d, J=8.8Hz, 1H; 7.82ppm (d, J=8.8Hz, 2H) , Example 6.
N-(2-/¾-butyl-3-[4-(3-chloropropoxy)ben^
compound of the general formula (ID, where X is chloro atom
' . ,
5.2 g 2-«-butyl-5-mesylamino-benzofuran (III) was mixed with 30 ml dichloromethane and to the resulting suspension 5.55 g 4-(3-chloropropoxy)benzoic acid chloride -the compound of the general formula (IV), where X and Y are chloro atom- was slowly added. The reaction mixture was cooled to 5°C and in 15 minutes, in four portions 3.89 g iron(III) chloride was added, keeping the temperature between 5-10°C. The mixture was stirred at 20°C for 1 hour, then heated to 40- 45°C and in 30 minutes 54 ml water was added. The mixture was stirred at that temperature for 30 minutes. The phases were, still warm, separated. The dichloromethane phase was washed by stirring with 2 x 16 ml 5% NaHCO3 solution, then with 2 x 16 ml water. The solvent was removed by evaporation.
Mass of the product: 9.13 g (98.4%)
Purity (HPLC) 89.6%.
After crystallisation (88%) from abs. ethanol, the purity of the product (by HPLC): 100%
Melting point: 109.8-1 10.2°C
The product is identical with the product prepared in Example 4.
Example 7. N-(2-ft-buty 1-3 -[4-(3 -chloropropoxy benzoy 1] benzofuran-5 -y Dmethanesulfonamide, compound of the general formula (II), where X is chloro atom
The reaction was performed as described in Example 6., but chlorobenzene was used as solvent, instead of dichloromethane.
Mass of the product: 97.6%
Purity (HPLC): 88.6% Example 8.
N-(2-½-butyl-3-r4-(3-chloropropoxy)be^
compound of the general formula (II), where X is chloro atom
The reaction was performed as described in Example J., but aluminum chloride was used instead of iron(III) chloride.
Yield of the product: 96.8%
- Purity (HPLC): 86.5%
- .
Example 9.
N-(2- 7-butyl-3-r4-(3-bromopropoxy)benzoyl1benzofuran-5-yl)methanesulfonamide, the compound of the general formula (II), where X is bromo atom
To the suspension of 5 g 2-n-butyr-5-mesylamino-benzofuran (III) in 35 ml dichloromethane was slowly added 5.19 g 4-(3-bromopropoxy)benzoyl chloride - the compound of the general formula (IV), where X is bromo atom and Y is chloro atom. The reaction mixture was cooled to 5°C and in 20 minutes, in five portions 9 g iron(III) chloride was added, maintaining the temperature between 5-10°C\ The mixture was stirred at 20°C for 1 hour, then heated to 40-45°C, and in 30 minutes 55 ml water was added. The mixture was stirred at that temperature for 40 minutes. The phases were, still warm, separated. The dichloromethane phase was washed by stirring with 2 x 16 ml 5% NaHCO3 solution, then with 2 x 16 ml water. The solvent was removed by evaporation.
Mass of the product: 8.1 g (93.4%)
Purity (HPLC) 88.2%.
The product is identical with the product prepared in Example 5. Example 10.
N-(2- -butyl-3- 4"(3-bromopropoxy)benzoyllbenzomran-5-yl)methanesulfonami the compound of the general formula (II), where X is bromo atom
■ .. '
The reaction was performed as described in Example 9., but chlorobenzene was used as solvent, instead of dichloromethane.
Mass of the product: Ί.9 g
Purity (HPLC): 86.7%
Example 11.
N-(2-«-bu l-3- 4-(3-brom0propoxy)benzoyllbenzofuran-5-yl)methanesulfonamide, the compound of the general formula (II), where X is bromo atom
The reaction was performed as described in Example 9., but aluminum chloride catalyst was used, instead of iron(III) chloride
Mass of the product: 8.0 g
Purity (HPLC): 85.6%
' , .
Example 12.
N- [2- -buty 1-3 - { 4- [(3 -dibuty lamino)propoxy ]benzoy 11-1 -benzofuran-5 -y Π- methanesulfonamide, the compound of the general formula (I)
5 g N-(2-«-butyl-3-[4-(3-chloropropoxy)benzoyl]benzofuran-5-yl)- methanesulfonamide -the compound of the general formula (II), where X is chloro atom- was dissolved in 90 ml methyl ethyl ketone, then 16.7 g dibutylamine and 6.46 g sodium iodide were added and the mixture was stirred for 16 hours. The reaction mixture was evaporated, 100 ml dichloromethane and 100 ml water were added. The phases were separated. The organic phase was washed by stirring with 50 ml 5% hydrochloric acid, then with 50 ml water. The solvent was distilled off. The dibutylamine recovered from the solvent was used in a next reaction.
Mass of the product: 5.9 g (100.0%)
Purity (HPLC): 98.7%
The product is purified through its oxalate salt (90%).
Purity of the oxalate salt (HPLC): 100%
1H NMR (DMSO): 0.8-0.9ppm (m, 9H); 1.2-1.5ppm (m, lOH); 1.67ppm (5\ 2H); 1.87ppm (5', 2H); 2.38ppm (t, J=7.2Hz, 4H); 2.57ppm (m, 2H); 2.81ppm (t, J=7.5Hz, 2H); 2.91ppm (s, 3.H); 9.51ppm (t, J=6.2Hz, 2H); 7.09ppm (d, J=8.8Hz, 2H); 7.24ppm (dd, J=8.9; 2.2Hz, IH); 7.38ppm (d, J=2.1Hz, IH); 7.65ppm (d, J=8.8Hz, lH); 7.81ppm (d, J=8.8Hz, 2H)
Example 13. N- 2-^-buty 1-3 - { 4- [(3 -dibutylamino)propoxy1 benzoyl } - 1 -benzofuran- 5 - yl] - methanesulfonamide, the compound of the general formula (I)
The reaction was performed as described in Example 12., but potassium iodide was used, instead of sodium iodide.
Mass of the product: 100.0%
Purity (HPLC): 97.8% ^
Example 14. N- 2-«-butyl-3-(4-[(3-dibutylamino)propoxylbenzoy -l-benzofuran-5-yl]- methanesulfonamide, the compound of the general formula (I)
The reaction was performed as described in Example 12., but acetone was used, instead of methyl ethyl ketone.
Mass of the product: 98.7%
Purity (HPLC): 97.1% Example 15.
N-[2-^-butyl-3-(4-f(3-dibutylamino)propoxy benzovU-l-benzofuran-5-yn- methanesulfonamide, the compound of the general formula (I)
The reaction was performed as described in Example 12., but for solvent, a 9:1 mixture of methyl ethyl ketone and toluene was used.
Yield of the product: 98.8% , /- . - . ' ·
Purity (HPLC): 98.7%
Example 16.
N-[2-^-butyl-3-(4-r(3-dibutylamino)propoxy1benzoy -l-benzofuran-5-yll- methanesulfonamide, the compound of the general formula (I)
The reaction was performed as described in Example 12., using N-(2-«- butyl-3-[4-(3-bromopropoxy)benzoyl]benzofuran-5-yl)methanesulfonamide -the compound of the general formula (II), where X is bromo atom- for starting material.
Yield of the product: 98.7%
Purity (HPLC): 97.7%
The product is identical with the product prepared in Example 12. -
Example 17.
N- [2-w-buty 1-3 - { 4- [(3 -dibuty lamino)propoxyl benzoyl } - 1 -benzofuran-5 - yll- methanesulfonamide, the compound of the general formula (I)
The reaction was performed as described in Example 12., with the difference that the starting material was N-(2-n-butyl-3-[4-(3-methanesulfonyloxy- propoxy)benzoyl]benzofuran-5-yl)methanesulfonamide -the compound of the general formula (II), where X is methanesulfonyloxy group- and sodium iodide was not used. ,
Yield of the product: 89.1% Purity (HPLC): 98.1% Example 18. N-[2-w-butyl-3- (4-f (3-dibutylamino)propoxyJbenzoyl }- 1 -benzofuran-5-νΠ- methanesulfonamide, the compound of the general formula (I)
The reaction was performed as described in Example 12., with the difference that the starting material was N-(2-«-butyl-3-[4-(3-tosyloxy- propoxy)benzoyl]benzofuran-5-yl)-methanesUlforiamide -the compound of the general formula (II), where X is tosyloxy group- and sodium iodide was not used.
Yield of the product: 97.81%
Purity (HPLC): 97.6% Example 19.
N-[2-«-butyl-3-(4- (3-dibutylamino)propoxylbenzoyl -l-benzofuran-5-yl1- methanesulfonamide, the compound of the general formula (I) - . , · 0.5 g N-(2-«-butyl-3-[4-(3-hydroxy-propoxy)-benzoyl]-benzofuran-5-yl)- methanesulfonamide -the compound of the general formula (II), where X is hydroxyl group- was dissolved in, 8 ml toluene. To the solution 1.5 g dibutylamine and 1.2 mol% [Ru(/?-cymene)Cl2]2 and 2.5 mol% l, l '-bis-(diphenylphosphino)- ferrocene catalysts were added and the reaction mixture was kept under reflux for 24 hours. The solvent was removed by evaporation, the residue was taken up in 10 ml dichloromethane and washed by stirring with 5 ml 1% hydrochloric acid, then with 10 ml water. The solvent was removed by evaporation.
Mass of the product: 0,51 g (82.5%)
Purity (HPLC): 92.4%
The product is identical with the product prepared according to Example 12. Example 20.
N-r2-¾-butyl-3-{4-f(3-dibutylamino)propoxylberi2oyl)-l-benzoruran-5-yl]- methanesulfonamide hydrogen chloride salt,
the compound of the general formula (la)
5 g dronedarone base was dissolved in 24 ml isopropanol and 0.98 g 37% hydrochloric acid was added to it. The mixture was cooled to 0°C and kept at that temperature for 5 hours. The precipitated white crystals were collected, washed with 3.5 ml isopropanol. The product was dried at 50°C under vacuum.
Mass of the product: 5.2 g (97.6%)
Purity (HPLC): 100%

Claims

Claims
1. Process for the preparation of N-[2-«-butyl-3-{4-[(3- dibutylamino)propoxy]benzoyl}-l-benzofuran-5-yl]methanesulfonamide of formula I
and its
Figure imgf000023_0001
at a benzofuran derivative of the general formula II
Figure imgf000023_0002
II
-wherein X represents chloro-, br mo- or iodo atom, hydroxyl- or activated hydroxy 1 group- is reacted with dibutylamine and, if desired, the salt of the product is formed.
2. The process according to claim 1., c h a r a c t a r i z e d in t h a t the reaction is carried out with excess of dibutylamine.
3. The process according to any of claims 1-21, cha rac ta rized in that the reaction is carried out in an organic solvent or in the mixture of organic solvents.
4. The process according to claim 3., charactarized in that the organic solvent is selected from ketones.
5. The process according to claim 4., c h a r a c t a r i z e d i n th t the ketone is acetone or methyl ethyl ketone.
6. The process according to claim 3., char ctarized in that as for mixture of organic solvents, the mixture of ketone and aromatic hydrocarbon is used. 7. The process according to claim 6., c h a r a c t a r i z e d in that as for aromatic hydrocarbon, toluene or xylene is used.
8. The process according to any of claims 1-7., c h a ra c ta riz e d i n that in the case where in the general formula II the meaning of X is chloro- or bromo atom or hydroxyl group, the reaction is carried out in the presence of a catalyst.
9. The process according to8., charactarized in that in the case where in the general formula II the meaning of X is chloro- or bromo atom, the catalyst is sodium- or potassium iodide.
10. The process according to claim 8., c h a racta rized in th at in the case where in the general formula II the meaning of X is hydroxyl group, the catalysts are [Ru(p-cymene)Cl2]2 and l, -bis-(diphenylphosphino)ferrocene or [Ru( -cymene)Cl2]2 and bis-(2-diphenylphosphinophenyl)-ester compounds. „
11. The process according to any of claims 1-10., cha r ctarized in t h a t the reaction is carried out at the boiling point of the solvents or at a temperature between 60-120°C.
12. The process according to any of claims 1-11., charactarized in t h a t in the case where in the general formula II the meaning of X is activated hydroxyl group, the activating group is mesyloxy- or substituted benzenesulfonyloxy group.
13. The process according to 12., c h a r cta rize d i n th a t the substituents of the substituted benzenesulfonyloxy group are selected from methyl group, nitro group or halogen atom.
14. The process according to any of claims 1-13., characta rized in that the benzofuran derivative of formula III
Figure imgf000025_0001
IV where
Y represents chloro- or bromo atom, X represents; halogen atom or protected hydroxyl group, and the resulting benzofuran derivative of the general formula II
Figure imgf000026_0001
-where the meaning of X is defined aboye- is reacted with dibutylamine and, if desired, the salt of the product is formed.
15. The process according to claim 14., c h a r a c t a r i z e d i n that the reaction of the compound of formula III with the compounds of the general formula IV is carried out in the presence of Friedel-Crafts catalyst.
16. The process according to claim 15., c h a r a c t a r i z e d i n t h a t aluminum chloride or iron(III) chloride are used as Friedel-Crafts catalysts.
17. The process according to claim 14., c h a r a c t a r i z e d i n that the reaction of the compound of formula III with the compounds of the general formula IV is carried out in halogenated solvents.
18., The process according to claim 17., c h a r a c t e r i z e d i n that dichloromethane, dichloroethane or chlorobenzene are used as halogenated solvents. ' ■ .. ' . ■ '
19. The process according to claim 14., c h a r a c t a r i z e d i n that the reaction of the compound of formula III with the compounds of the general formula IV is carried out in nitrobenzene.
20. The process according to claim 14., c h a r a c t a r i z e d i n that the reaction of the compound of formula III with the compounds of the general formula IV is carried out at a temperature between 10-80 °C.
21. The process according to any of claims 1-13., c h a racte rized in that
a.) a compound of the general formula VI
Figure imgf000027_0001
where X represents chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group- . ^
is subjected to hydrogenation reaction,
and then
b.) the resulting compound of the general formula V,
Figure imgf000027_0002
where X represents chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group- is mesylated,
and
c.) the resulting benzofuran derivative of the general formula II
Figure imgf000027_0003
II where X represents chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group- is reacted with dibutylamine and, if desired, the thus obtained compound of the general formula I is transformed into its salt.
22. Reaction step a.) of the process according to claim 21., charactarized i, n that the hydrogenation reaction is carried out in the presence of catalyst.
23. The process according to claim 22., c h a racta rized in th at palladium or platinum are applied as catalysts.
24. Reaction step a.) of the process according to / claim 21., charactarized in that the reaction is carried out in organic solvent at a temperature between 10-80 °C.
25. Reaction step b.) of the process according to claim 21., charactarized in that methanesulfonyl chloride or methanesulfonic anhydride are used as mesylating agents.
26. Reaction step b.) of the process according to claim 21., charactarized in that the reaction is carried out in inert solvents. 27. The process according to claim 26., c ha rac ta rized i n th a t ethers or halogenated hydrocarbons are used as inert solvents.
28. Reaction step b.) of the process according to claim 21., charactarized in that the reaction is carried out at a temperature between 5-80 °C.
29. Reaction step b.) of the process according to claim 21., characterized in that the reaction is carried out in the presence of a base.
Figure imgf000029_0001
30. The process according to claim 29., c h a racte rized in th a t amine compounds are used as base.
31. tha t pyrid
Figure imgf000029_0002
where X is chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group.
Figure imgf000029_0003
where X is chloro-, bromo- or iodo atom, hydroxyl- or activated hydroxyl group.
35. The compounds as defined in claim 34., where X is mesyloxy group or substituted benzenesulfonyloxy group.
The compounds of the general formula VI,
Figure imgf000030_0001
VI where X is chloro or iodo atom, hydroxyl- or activated hydroxyl group.
37. The eompounds. as defined in claim 36., where X is mesyloxy group substituted benzenesulfonyloxy group.
PCT/HU2010/000128 2009-12-08 2010-11-23 New process for the preparation of dronedarone WO2011070380A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
RU2012128568/04A RU2012128568A (en) 2009-12-08 2010-11-23 NEW METHOD FOR PRODUCING A DRONEDARON
MX2012006654A MX2012006654A (en) 2009-12-08 2010-11-23 New process for the preparation of dronedarone.
CN2010800629901A CN102741238A (en) 2009-12-08 2010-11-23 New process for the preparation of dronedarone
CA2781647A CA2781647A1 (en) 2009-12-08 2010-11-23 New process for the preparation of dronedarone
BR112012013753A BR112012013753A2 (en) 2009-12-08 2010-11-23 "process for the preparation of dronedarone"
AU2010329655A AU2010329655B2 (en) 2009-12-08 2010-11-23 New process for the preparation of dronedarone
JP2012542624A JP2013512944A (en) 2009-12-08 2010-11-23 A novel method for preparing dronedarone
SG2012041927A SG181562A1 (en) 2009-12-08 2010-11-23 New process for the preparation of dronedarone
EP10809325A EP2509971A1 (en) 2009-12-08 2010-11-23 New process for the preparation of dronedarone
US13/479,615 US8501971B2 (en) 2009-12-08 2012-05-24 Process for the preparation of dronedarone
IL220170A IL220170A0 (en) 2009-12-08 2012-06-04 New process for the preparation of dronedarone
US13/905,624 US8889734B2 (en) 2009-12-08 2013-05-30 Process for the preparation of dronedarone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP0900759 2009-12-08
HU0900759A HUP0900759A2 (en) 2009-12-08 2009-12-08 Novel process for producing dronedarone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/479,615 Continuation US8501971B2 (en) 2009-12-08 2012-05-24 Process for the preparation of dronedarone

Publications (1)

Publication Number Publication Date
WO2011070380A1 true WO2011070380A1 (en) 2011-06-16

Family

ID=89989418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2010/000128 WO2011070380A1 (en) 2009-12-08 2010-11-23 New process for the preparation of dronedarone

Country Status (16)

Country Link
US (2) US8501971B2 (en)
EP (1) EP2509971A1 (en)
JP (1) JP2013512944A (en)
CN (1) CN102741238A (en)
AR (1) AR079269A1 (en)
AU (1) AU2010329655B2 (en)
BR (1) BR112012013753A2 (en)
CA (1) CA2781647A1 (en)
HU (1) HUP0900759A2 (en)
IL (1) IL220170A0 (en)
MX (1) MX2012006654A (en)
RU (1) RU2012128568A (en)
SG (1) SG181562A1 (en)
TW (1) TW201144291A (en)
UY (1) UY33094A (en)
WO (1) WO2011070380A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012032545A1 (en) 2010-09-08 2012-03-15 Cadila Healthcare Limited Processes for preparing dronedarone and its intermediates
WO2012004658A3 (en) * 2010-07-09 2012-05-18 Frichem Private Limited Process for preparation of n-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]methanesulfonamide, acid addition salts and product thereof
WO2013014478A1 (en) * 2011-07-26 2013-01-31 Sanofi Reductive amination process for preparation of dronedarone using carboxyl intermediary compound
WO2013014479A1 (en) * 2011-07-26 2013-01-31 Sanofi Reductive animation process for preparation of dronedarone using aldehyde intermediary compound
FR2983198A1 (en) * 2011-11-29 2013-05-31 Sanofi Sa PROCESS FOR THE PREPARATION OF 5-AMINO-BENZOYL-BENZOFURAN DERIVATIVES
EP2539331B1 (en) * 2010-02-23 2014-10-08 Laboratorio Chimico Internazionale S.p.A. Novel process for the manufacture of dronedarone
US9174958B2 (en) 2010-06-18 2015-11-03 Sanofi Process for the preparation of dronedarone
US9174959B2 (en) 2011-03-29 2015-11-03 Sanofi Process for preparation of dronedarone by N-butylation
US9193703B2 (en) 2011-03-29 2015-11-24 Sanofi Process for preparation of dronedarone by mesylation
US9221777B2 (en) 2012-01-20 2015-12-29 Sanofi Process for preparation of dronedarone by the use of dibutylaminopropanol reagent
US9221778B2 (en) 2012-02-13 2015-12-29 Sanofi Process for preparation of dronedarone by removal of hydroxyl group
US9238636B2 (en) 2012-05-31 2016-01-19 Sanofi Process for preparation of dronedarone by Grignard reaction
US9249119B2 (en) 2012-02-14 2016-02-02 Sanofi Process for the preparation of dronedarone by oxidation of a sulphenyl group
US9334254B2 (en) 2010-03-30 2016-05-10 Sanofi Process for preparing sulfonamidobenzofuran derivatives
US9382223B2 (en) 2012-02-22 2016-07-05 Sanofi Process for preparation of dronedarone by oxidation of a hydroxyl group

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0900759A2 (en) * 2009-12-08 2011-11-28 Sanofi Aventis Novel process for producing dronedarone
FR2957079B1 (en) 2010-03-02 2012-07-27 Sanofi Aventis PROCESS FOR THE SYNTHESIS OF CETOBENZOFURAN DERIVATIVES
FR2958291B1 (en) 2010-04-01 2013-07-05 Sanofi Aventis PROCESS FOR PREPARING AMINO-BENZOFURAN DERIVATIVES
FR2962731B1 (en) 2010-07-19 2012-08-17 Sanofi Aventis PROCESS FOR THE PREPARATION OF AMINO-BENZOYL-BENZOFURAN DERIVATIVES
FR2963006B1 (en) 2010-07-21 2013-03-15 Sanofi Aventis PROCESS FOR THE PREPARATION OF NITRO-BENZOFURAN DERIVATIVES
HUP1000386A2 (en) 2010-07-22 2012-05-29 Sanofi Sa Novel process for producing dronedarone
CN102653530A (en) * 2011-03-04 2012-09-05 浙江省医学科学院 Preparation method and application of benzofuran derivate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0471609A1 (en) * 1990-08-06 1992-02-19 Sanofi Benzofuran Derivatives, Benzothiophenes, Indoles or Indolizines, Process for Production and Compositions containing them
WO2002048078A1 (en) 2000-12-11 2002-06-20 Sanofi-Synthelabo 2-butyl-3-(4-[3(dibutylamino)propoxy]benzoyl)-5-nitro-benzofuran hydrochloride and preparation thereof
WO2002048132A1 (en) 2000-12-11 2002-06-20 Sanofi-Synthelabo Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate
WO2003040120A1 (en) * 2001-11-08 2003-05-15 Isp Investments Inc. Process for the preparation of dronedarone

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833262A1 (en) 2001-12-06 2003-06-13 Rhodia Chimie Sa PROCESS FOR MONOSULFONYLATION OF AN AMINOBENZOFURANNE OR AMINOBENZOTHIOPHENE COMPOUND
DE10237819A1 (en) * 2002-08-19 2004-03-04 Bayer Ag 5-Nitrobenzofurane
CN101153012B (en) * 2006-09-29 2010-06-23 北京德众万全药物技术开发有限公司 Novel method of producing dronedarone key intermediate
TW201111354A (en) 2009-05-27 2011-04-01 Sanofi Aventis Process for the production of Dronedarone intermediates
UY32656A (en) 2009-05-27 2010-12-31 Sanofi Aventis PROCEDURE TO PRODUCE BENZOFURANS
HUP0900759A2 (en) * 2009-12-08 2011-11-28 Sanofi Aventis Novel process for producing dronedarone
HUP1000010A2 (en) 2010-01-08 2011-11-28 Sanofi Sa Process for producing dronedarone
FR2957079B1 (en) 2010-03-02 2012-07-27 Sanofi Aventis PROCESS FOR THE SYNTHESIS OF CETOBENZOFURAN DERIVATIVES
FR2958290B1 (en) 2010-03-30 2012-10-19 Sanofi Aventis PROCESS FOR THE PREPARATION OF SULFONAMIDO-BENZOFURAN DERIVATIVES
FR2958291B1 (en) 2010-04-01 2013-07-05 Sanofi Aventis PROCESS FOR PREPARING AMINO-BENZOFURAN DERIVATIVES
HUP1000330A2 (en) 2010-06-18 2011-12-28 Sanofi Sa Process for the preparation of dronedarone and the novel intermediates
FR2962731B1 (en) 2010-07-19 2012-08-17 Sanofi Aventis PROCESS FOR THE PREPARATION OF AMINO-BENZOYL-BENZOFURAN DERIVATIVES
FR2963006B1 (en) 2010-07-21 2013-03-15 Sanofi Aventis PROCESS FOR THE PREPARATION OF NITRO-BENZOFURAN DERIVATIVES
HUP1000386A2 (en) 2010-07-22 2012-05-29 Sanofi Sa Novel process for producing dronedarone
FR2973027A1 (en) 2011-03-24 2012-09-28 Sanofi Aventis PROCESS FOR THE SYNTHESIS OF CETOBENZOFURAN DERIVATIVES
HUP1100166A2 (en) 2011-03-29 2012-12-28 Sanofi Sa Reductive amination process for preparation of dronedarone using amine intermediary compound
HUP1100165A2 (en) 2011-03-29 2012-12-28 Sanofi Sa Process for preparation of dronedarone by n-butylation
HUP1100167A2 (en) 2011-03-29 2012-11-28 Sanofi Sa Process for preparation of dronedarone by mesylation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0471609A1 (en) * 1990-08-06 1992-02-19 Sanofi Benzofuran Derivatives, Benzothiophenes, Indoles or Indolizines, Process for Production and Compositions containing them
EP0471609B1 (en) 1990-08-06 1996-11-27 Sanofi Benzofuran Derivatives, Benzothiophenes, Indoles or Indolizines, Process for Production and Compositions containing them
WO2002048078A1 (en) 2000-12-11 2002-06-20 Sanofi-Synthelabo 2-butyl-3-(4-[3(dibutylamino)propoxy]benzoyl)-5-nitro-benzofuran hydrochloride and preparation thereof
WO2002048132A1 (en) 2000-12-11 2002-06-20 Sanofi-Synthelabo Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate
WO2003040120A1 (en) * 2001-11-08 2003-05-15 Isp Investments Inc. Process for the preparation of dronedarone

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2539331B1 (en) * 2010-02-23 2014-10-08 Laboratorio Chimico Internazionale S.p.A. Novel process for the manufacture of dronedarone
US9334254B2 (en) 2010-03-30 2016-05-10 Sanofi Process for preparing sulfonamidobenzofuran derivatives
US9174958B2 (en) 2010-06-18 2015-11-03 Sanofi Process for the preparation of dronedarone
WO2012004658A3 (en) * 2010-07-09 2012-05-18 Frichem Private Limited Process for preparation of n-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]methanesulfonamide, acid addition salts and product thereof
WO2012032545A1 (en) 2010-09-08 2012-03-15 Cadila Healthcare Limited Processes for preparing dronedarone and its intermediates
US9193703B2 (en) 2011-03-29 2015-11-24 Sanofi Process for preparation of dronedarone by mesylation
US9174959B2 (en) 2011-03-29 2015-11-03 Sanofi Process for preparation of dronedarone by N-butylation
US9611242B2 (en) 2011-03-29 2017-04-04 Sanofi Process for preparation of dronedarone by N-butylation
WO2013014479A1 (en) * 2011-07-26 2013-01-31 Sanofi Reductive animation process for preparation of dronedarone using aldehyde intermediary compound
WO2013014478A1 (en) * 2011-07-26 2013-01-31 Sanofi Reductive amination process for preparation of dronedarone using carboxyl intermediary compound
WO2013079866A1 (en) * 2011-11-29 2013-06-06 Sanofi Method for preparing 5-amino-benzoyl-benzofuran derivatives
FR2983198A1 (en) * 2011-11-29 2013-05-31 Sanofi Sa PROCESS FOR THE PREPARATION OF 5-AMINO-BENZOYL-BENZOFURAN DERIVATIVES
US9499507B2 (en) 2011-11-29 2016-11-22 Sanofi Method for preparing 5-amino-benzoyl-benzofuran derivatives
US9221777B2 (en) 2012-01-20 2015-12-29 Sanofi Process for preparation of dronedarone by the use of dibutylaminopropanol reagent
US9708281B2 (en) 2012-01-20 2017-07-18 Sanofi Process for preparation of dronedarone by the use of dibutylaminopropanol reagent
US9221778B2 (en) 2012-02-13 2015-12-29 Sanofi Process for preparation of dronedarone by removal of hydroxyl group
US9701654B2 (en) 2012-02-13 2017-07-11 Sanofi Process for preparation of dronedarone by removal of hydroxyl group
US9249119B2 (en) 2012-02-14 2016-02-02 Sanofi Process for the preparation of dronedarone by oxidation of a sulphenyl group
US9382223B2 (en) 2012-02-22 2016-07-05 Sanofi Process for preparation of dronedarone by oxidation of a hydroxyl group
US9238636B2 (en) 2012-05-31 2016-01-19 Sanofi Process for preparation of dronedarone by Grignard reaction

Also Published As

Publication number Publication date
UY33094A (en) 2011-07-29
AR079269A1 (en) 2012-01-04
HU0900759D0 (en) 2010-01-28
AU2010329655A1 (en) 2012-06-21
RU2012128568A (en) 2014-01-20
CN102741238A (en) 2012-10-17
BR112012013753A2 (en) 2015-09-15
JP2013512944A (en) 2013-04-18
AU2010329655B2 (en) 2014-01-16
SG181562A1 (en) 2012-07-30
US20130261321A1 (en) 2013-10-03
US20120289717A1 (en) 2012-11-15
HUP0900759A2 (en) 2011-11-28
US8889734B2 (en) 2014-11-18
IL220170A0 (en) 2012-07-31
MX2012006654A (en) 2012-06-25
EP2509971A1 (en) 2012-10-17
TW201144291A (en) 2011-12-16
CA2781647A1 (en) 2011-06-16
US8501971B2 (en) 2013-08-06

Similar Documents

Publication Publication Date Title
WO2011070380A1 (en) New process for the preparation of dronedarone
EP2521720B1 (en) New process for the preparation of dronedarone
JP2013528641A (en) Method for preparing dronedarone
JP4437004B2 (en) 2-Butyl-3- (4- [3- (dibutylamino) propoxy] benzoyl) -5-nitrobenzofuran hydrochloride and its preparation
US8816103B2 (en) Process for the preparation of dronedarone
US8536350B2 (en) Process for the manufacture of dronedarone
WO2013014479A1 (en) Reductive animation process for preparation of dronedarone using aldehyde intermediary compound
WO2013014480A1 (en) Process for preparation of dronedarone using amide intermediary compound
CA2612599A1 (en) Precursor compounds to antiarrhythmic benzolfuran compounds, methods of synthesis and methods of use
KR20120094090A (en) New process for the preparation of dronedarone

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080062990.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10809325

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2781647

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010329655

Country of ref document: AU

Ref document number: 220170

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2012542624

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010809325

Country of ref document: EP

Ref document number: MX/A/2012/006654

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1525/MUMNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2010329655

Country of ref document: AU

Date of ref document: 20101123

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127017392

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012128568

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012013753

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012013753

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120606